# US 7,745,588 B2 · Antibodies to a paralytic peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,588 B2
- Document ID: US7745588B2
- Status: Granted
- Kind: B2
- Application number: 11/834,916
- Filed: 2007-08-07
- Published: 2008-04-03
- Granted: 2010-06-29
- Earliest claimed: 2002-11-18
- Assignees: BioProspecting NB Inc.
- Inventors: John M. Stewart; Bradley J. Steeves; Karl Vernes
- Web page: https://patentgrep.com/patent/US7745588B2

## CPC

- C07K 14/47: from mammals
- A61K 38/1709: {from mammals}
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/06: Antimigraine agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxillary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.

## Claims

### Claim 1

An isolated antibody that specifically binds to an epitope within the sequence DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:1).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is a polyclonal antibody.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 4 (depends on 1)

An antibody fragment of the antibody of claim 1, wherein the antibody fragment binds to an epitope within the sequence of SEQ ID NO: 1.

### Claim 5 (depends on 4)

The antibody fragment of claim 4, comprising a Fab fragment, a VH region or a FY region.

### Claim 6 (depends on 5)

The antibody fragment of claim 5, comprising a F(ab′)2 fragment.

### Claim 7 (depends on 5)

The antibody fragment of claim 5, comprising a Fab′ fragment.

### Claim 8 (depends on 4)

The antibody fragment of claim 4, comprising a single-chain Fv monoclonal antibody.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody is labeled with a detectable marker.

### Claim 10 (depends on 1)

The antibody of claim 1, wherein the antibody is a chimeric antibody.

### Claim 11 (depends on 1)

The antibody of claim 1, wherein the antibody is a humanized antibody.

### Claim 12 (depends on 1)

A method for detecting the presence of a peptide comprising the sequence DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:1), comprising:
a) contacting a sample containing a peptide comprising the sequence of SEQ ID NO:1 under conditions suitable for the binding of the antibody of claim 1 to the peptide of SEQ ID NO:1; and
b) detecting antibody bound to the peptide of SEQ ID NO: 1 in the sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the peptide is detected using an ELISA assay.

### Claim 14 (depends on 12)

The method of claim 12, wherein the peptide is bound to a target receptor on the surface of a cell.

### Claim 15 (depends on 12)

The method of claim 12, wherein the peptide is radioactively labeled.

### Claim 16 (depends on 12)

The method of claim 12, wherein the peptide is fluorescently tagged.